Compare GSK plc (GSK) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Under Armour Inc Class A — how do they compare? GSK plc trades at $52.56 (market cap $101.34B), while Under Armour Inc Class A trades at $7 (market cap $2.89B). The key difference: GSK plc is far larger — about 35.1× Under Armour Inc Class A's market cap, and GSK plc pays a 3.49% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| GSK | UA | |
|---|---|---|
Market Cap | $101.34B | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $7.88 |
52-Week Low | $36.20 | $3.96 |
Enterprise Value | $121.95B | $4.52B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Under Armour (UA) trades at $6.915, up 6.88% today, with a bullish technical signal from moving averages and oscillators. The company reported a net loss of -$201.27 million in 2025, with a negative net income margin of -9.98%, though it beat earnings expectations in two of the last three quarters. Recent news includes a Dodge collaboration and a 1.2 million share purchase by Prem Watsa's Fairfax Financial, signaling institutional interest amid ongoing business restructuring.
The outlook remains challenged by declining revenues and persistent losses, but low P/S of 0.58 and analyst buy ratings (40.3%) suggest potential if turnaround efforts gain traction. Key risks include execution missteps, competitive pressure, and further revenue erosion, requiring careful monitoring of 2027 guidance for sustainable recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
